Menin is the switch that lets TGF-beta turn parathyroid hormone down - and it works on secretion, not just growth
also called menin TGF-beta parathyroid · PTH secretion menin · parathyroid cell proliferation TGF-beta
In parathyroid cells, a local signal called TGF-beta normally tells the gland both to stop growing and to make less parathyroid hormone. Menin is required for that message to be heard: knock menin down and the cells ignore it and keep secreting.
The same thing, for a scientist
This is the normal-parathyroid-biology entry the endocrine beat has been missing, and it is also the most specific available mechanism for the labelled PTH signal. In primary parathyroid cells from patients with secondary hyperparathyroidism, TGF-beta - which is expressed in parathyroid endocrine cells - inhibited both **proliferation and PTH secretion**. Both responses were lost when menin was specifically inactivated with antisense oligonucleotides, and TGF-beta affected neither proliferation nor PTH production in parathyroid cells from a MEN1 patient [E1]. The authors conclude that TGF-beta is an autocrine/paracrine negative regulator of the parathyroid and that menin is required for its action.
Why the secretion half is the important half
Every other parathyroid entry in this beat is about neoplasia - adenoma, hyperplasia, penetrance curves, decades of latency. Those all require growth, which takes time. This paper shows menin is also required for restraint of secretion, which does not. A cell does not need to divide to secrete more PTH; it needs only to stop being told not to.
That converts the labelled finding - intact PTH increased in 34% of revumenib-treated patients, median exposure 2.5 months 2 - from an implausibly fast tumour-suppressor effect into a plausible acute pharmacology. A drug that removes menin function in the parathyroid chief cell should, on this mechanism, raise PTH within weeks, with no adenoma anywhere. hyp-menin-inhibition-perturbs-parathyroid-axis-dose-dependently proposes exactly this and has until now had no cited mechanism for it; this is the mechanism.
What it does not settle
The menin knockdown is antisense in cultured human parathyroid cells, not pocket occupancy by an inhibitor. Nothing is known about whether a menin inhibitor engages the TGF-beta arm at all. A raw PubMed search on 2026-09-19 for menin inhibitors (revumenib, ziftomenib, MI-2/463/503 or 'menin inhibitor') co-occurring with parathyroid, PTH or hypercalcaemia in title or abstract returns zero records, against 118 records for 'menin inhibitor' and 167 for 'menin AND parathyroid' separately. No one has ever put a menin inhibitor on a parathyroid cell. That is the cheapest missing experiment in this entire beat.
The competing explanation remains live
The label reports creatinine increased in 38% and phosphate increased in 51% 2. Ordinary secondary hyperparathyroidism in a sick, renally impaired population explains a raised PTH without invoking menin at all, and it is the null this mechanism has to beat. What this entry adds is that the on-target explanation is now mechanistically specified rather than merely asserted, and it makes a distinguishing prediction: an on-target effect should track drug exposure and should resolve off drug, whereas renal secondary hyperparathyroidism should track creatinine and phosphate.
| tissue | parathyroid chief cell |
|---|---|
| pathway | TGF-beta autocrine/paracrine -> menin-dependent -> inhibition of proliferation AND of PTH secretion |
| manipulation | menin antisense oligonucleotide; MEN1 patient cells |
| timescale implication | secretory restraint can be lost without any growth, so a PTH rise within weeks is mechanistically available |
| menin inhibitor tested | false |
| literature search 2026 09 19 | 0 records for menin inhibitor terms AND parathyroid/PTH/hypercalcaemia in Title/Abstract, against 118 and 167 records for the halves separately |
- If menin restrains PTH secretion and not only parathyroid growth, then the parathyroid effect of a menin inhibitor arrives in weeks, well inside a paediatric treatment course, and does not require the decades the MEN1 latency argument assumes.
- Chronically raised PTH in a growing child acts on bone, and this beat already carries an irreversible juvenile-rat growth-plate finding and raised alkaline phosphatase in 33% of patients.
- No one has ever exposed a parathyroid cell to a menin inhibitor, so the most direct test of the beat's central toxicity hypothesis has simply not been run.
- Does revumenib, at clinically achieved concentrations, abolish the TGF-beta suppression of PTH secretion in primary human parathyroid cells? This has never been attempted and needs one experiment.
- Does intact PTH fall after the last dose? No off-treatment PTH value exists anywhere in the public record.
- Is the PTH rise exposure-dependent within the treated population - answerable today from the sponsor's PK and laboratory database without recruiting anyone.
- E1moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
Menin is required for TGF-beta to inhibit parathyroid cell proliferation and PTH secretion; menin inactivation abolishes both responses, and parathyroid cells from a MEN1 patient do not respond to TGF-beta.
Menin inactivation leads to loss of transforming growth factor beta inhibition of parathyroid cell proliferation and parathyroid hormone secretion. · Sowa H, Kaji H, Kitazawa R, Kitazawa S, Tsukamoto T, Yano S, et al. · Cancer Research 2004What this evidence cannot show
Primary human parathyroid cells from secondary hyperparathyroidism, which are already abnormal; antisense knockdown rather than pocket inhibition; the MEN1 arm is a single patient; 2004 methodology with no genome-wide confirmation.
Evidence that argues against this (1)
- The second approved menin inhibitor's label reports no parathyroid finding at all - no Endocrine disorders heading, no PTH, calcium or phosphate row - so if this were a straightforward class pharmacology it should have shown up twice and did not. Kura Oncology et al. 2025
- E2established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database
Intact PTH increased in 34% of patients on revumenib, alongside creatinine increased in 38% and phosphate increased in 51%, with hyperparathyroidism listed under Endocrine disorders.
REVUFORJ (revumenib) tablets, for oral use - US Prescribing Information (SPL version 5, published 20 Feb 2026) · Syndax Pharmaceuticals, Inc. · DailyMed / FDA Structured Product Label, setid 6eb3cdbc-0e74-477d-82d6-3bb172d3f63f 2026What this evidence cannot show
Laboratory-abnormality table with denominators of 139-240; no grade 3-4 rate, no magnitude, no time course, no off-treatment values, and no paediatric breakdown.
Evidence that argues against this (1)
- FAERS contains zero reports of any of 20 endocrine or bone-mineral terms for revumenib, which is consistent with spontaneous reporting missing asymptomatic laboratory abnormalities rather than with absence of effect - see ana-faers-menin-inhibitor-endocrine-disproportionality. Syndax Pharmaceuticals et al. 2026
- supports →Hypothesis: the PTH rise on menin inhibitors is on-target and exposure-dependent, not renal
Supplies the mechanism the hypothesis lacked: menin is required for TGF-beta to restrain PTH SECRETION, not only parathyroid growth, so a PTH rise within a 2.5-month exposure is mechanistically available without any adenoma
Makes the on-target reading of the labelled 34% intact-PTH elevation mechanistically specific rather than asserted
Normal parathyroid physiology underlying the MEN1 manifestation: menin-dependent TGF-beta restraint of chief-cell proliferation and secretion
- ← co-occurs withThe parathyroid does not need the rest of the body: deleting menin only there causes neoplasia and hypercalcaemia
Growth arm and secretion arm of the same parathyroid menin function; only the secretion arm operates on a timescale compatible with a 2.5-month drug exposure
Takes the one step never taken: the mechanism was established with antisense knockdown in 2004 and no menin inhibitor has ever been applied to a parathyroid cell